Drug intelligence / Profile preview

EGFR dual-targeting CAR-NK cells

Development stage: Preclinical
Lead developer: Cytovia
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Locoregional, Intracranial, Intravenous

Overview

EGFR dual-targeting CAR-NK cells are an investigational 'off-the-shelf' cell therapy developed by Cytovia Therapeutics, which acquired worldwide rights from CytoImmune Therapeutics. This therapy utilizes Natural Killer (NK) cells engineered with Chimeric Antigen Receptors (CARs) designed to target the Epidermal Growth Factor Receptor (EGFR) at two distinct sites. It is being developed for the treatment of glioblastoma and other solid tumors, based on promising preclinical data.

Other names: EGFR Dual-targeting CAR-NK cell therapy

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)EGFRvIII (Epidermal growth factor receptor variant III)

Beyond the preview

Go deeper on EGFR dual-targeting CAR-NK cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGFR dual-targeting CAR-NK cells.

Explore the full profile